Life Biosciences
PulseAugur coverage of Life Biosciences — every cluster mentioning Life Biosciences across labs, papers, and developer communities, ranked by signal.
1 day(s) with sentiment data
-
Geneticist's age-reversal eye therapy enters human trials
Yuancheng (Ryan) Lu, a geneticist at the Whitehead Institute, has developed a gene therapy that shows promise in reversing age-related vision loss. His technique, based on reprogramming cells using a modified set of Yam…
-
Longevity field's cellular reprogramming theory faces human trial reality check
A groundbreaking human trial has begun for a gene therapy aimed at partially reprogramming older cells to a younger state, a development that could validate key theories in the longevity medicine field. This early-stage…
-
First Human Receives Cellular Rejuvenation Therapy in Landmark Trial
A biotechnology startup, Life Biosciences, has initiated a clinical trial treating the first human with a cellular reprogramming therapy aimed at reversing aging. This therapy, which utilizes three Yamanaka factors to r…
-
Life Biosciences begins human trials for age-reversal drug
Life Biosciences has initiated its first human trials for an experimental drug designed to reverse age-related conditions. The drug employs a "reprogramming" strategy to combat the effects of aging.
-
Life Biosciences trials nerve regeneration treatment for glaucoma
Life Biosciences has dosed its first volunteer with an experimental treatment aimed at regenerating healthy eye nerves for glaucoma patients. This marks a significant advancement in the pursuit of reversing age-related …
-
MIT Tech Review: Cell reprogramming for aging reversal and interoception research gain momentum
MIT Technology Review's newsletter, The Download, highlights two emerging areas of scientific research: the "reprogramming" of cells to reverse aging and the study of interoception, the internal sense of bodily feelings…
-
Life BioSciences begins Phase 1 trial for optic neuropathy drug
Life BioSciences has announced a significant milestone with the first patient dosed in a Phase 1 clinical trial for ER-100, an epigenetic restoration drug candidate. This drug targets optic neuropathies, a group of diso…
-
David Sinclair to test oral rejuvenation drug in XPrize competition
Longevity scientist David Sinclair is preparing to test an oral drug mixture, code-named SL-100, for whole-body rejuvenation. This initiative is part of a $101 million XPrize competition aimed at restoring individuals t…